Physician profile
Kevin Moore
NPI 1740270016
$2,868.12
in general payments reported to CMS, 2019-2025
31 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.97 · 2020: $328 · 2021: $527 · 2022: $262 · 2023: $461 · 2024: $758 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $383.04 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $381.64 | 2020-2025 | |
| Abbvie INC. | $353.65 | 2021-2025 | |
| Lilly USA, LLC | $303.52 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $223.89 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $170.44 | 2022-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $166.83 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.35 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $88.76 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.41 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $69.01 | 2022-2023 | |
| Exact Sciences Corporation | $57.36 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $47.87 | 2023-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $39.43 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $37.89 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $33.01 | 2022 | |
| Allergan, INC. | $32.77 | 2020 | |
| Corcept Therapeutics | $32.21 | 2023-2024 | Korlym |
| Amarin Pharma, INC. | $28.69 | 2020 | |
| Boston Scientific Corporation | $23.01 | 2023 | Watchman Access System |
| Mylan Specialty L.P. | $22.20 | 2021 | |
| Axsome Therapeutics, INC. | $21.51 | 2025 | Auvelity |
| Hologic Sales and Service, LLC | $21.40 | 2025 | Aptima |
| Dermira, INC. | $18.28 | 2020 | |
| Vertos Medical, INC. | $18.05 | 2024 | Mild Device Kit |
| Bayer Healthcare Pharmaceuticals INC. | $17.49 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.47 | 2025 | Trintellix |
| Abbott Laboratories | $17.45 | 2024 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $14.25 | 2023 | Inspire |
| Ferring Pharmaceuticals INC. | $14.07 | 2024 | Rebyota |
| Si-Bone, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.